Open-label safety assessment of bilastine in elderly patients with allergic rhinoconjunctivitis and/or urticaria.

Autor:	Sologuren A; From the Pharmacovigilance Unit, Faes Farma S. A., Leioa-Bizkaia, Spain., Viñas R; Centre d'Atenció Primaria Amadeu Torner, Barcelona, Spain., Cordón E; Centro de Salud Los Cármenes, Madrid, Spain., Riesgo SE; Centre d'Atenció Primaria Amadeu Torner, Barcelona, Spain., Del Mar Forés M; Centre d'Atenció Primaria Amadeu Torner, Barcelona, Spain., Senán MR; Centre d'Atenció Primaria El Clot, Barcelona, Spain., Fernández S; From the Pharmacovigilance Unit, Faes Farma S. A., Leioa-Bizkaia, Spain., Labeaga L; Medical Department, Faes Farma S. A., Leioa-Bizkaia, Spain., Ruiz-Miján M; From the Pharmacovigilance Unit, Faes Farma S. A., Leioa-Bizkaia, Spain.
Jazyk:	angličtina
Zdroj:	Allergy and asthma proceedings [Allergy Asthma Proc] 2018 Jul 20; Vol. 39 (4), pp. 299-304. Date of Electronic Publication: 2018 Mar 20.
DOI:	10.2500/aap.2018.39.4136
Abstrakt:	Background: Bilastine is an H1-antihistamine approved for symptomatic treatment of patients with allergic rhinoconjunctivitis or urticaria. The safety profile of bilastine in clinical trials of allergic rhinoconjunctivitis or urticaria, assessed by type and frequency of adverse events (AE), was similar to that of placebo. Objective: As part of the risk management plan for bilastine, the safety profile of bilastine in the elderly was assessed. Methods: A prospective, multicenter, observational, open-label, 3-month follow-up study was performed to assess the safety profile of bilastine 20 mg in patients aged ≥65 years with allergic rhinoconjunctivitis and/or urticaria. Results: A total of 74 of 146 patients (50.7%) reported 129 treatment-emergent AEs (TEAE) during the study period. The incidence of TEAEs was low, with monthly and quarterly rates of 0.29 (95% confidence intervals [CI], 0.229-0.367) and 0.88 (95% CI, 0.688-1.100), respectively. Monthly and quarterly incidence rates were 0.04 (95% CI, 0.016-0.082) and 0.12 (95% CI, 0.048-0.246), respectively, for related TEAEs (eight TEAEs in seven patients) and were 0.02 (95% CI, 0.003-0.048) and 0.05 (95% CI, 0.010-0.143), respectively, for serious TEAEs (five TEAES in three patients). All serious TEAEs were considered to be unrelated to bilastine. Conclusion: Bilastine 20 mg showed a favorable safety profile with a low incidence of TEAEs in patients aged ≥65 years. The results were in accordance with the known safety profile of bilastine 20 mg and incidence of AEs reported in previous studies and described in the approved summary of product characteristics.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu